Methadone used at Overmountain Recovery

Methadone used at Overmountain Recovery belongs to the book’s account of medication-assisted treatment, where the same medicine appears in distinct settings: as an option for people seeking treatment for opioid addiction and as part of hospital care for some newborns experiencing withdrawal. Its significance lies not in a single patient’s story, but in the practical and political questions surrounding whether medication-based care is available, accepted, and sustained.

Treatment and Maintenance Context

The book places Methadone used at Overmountain Recovery among the medications offered through medication-assisted treatment, alongside buprenorphine. A private Virginia treatment center that accepted patients using either medication provided one route into care for Tess Henry during the final month of her pregnancy. She was taking Subutex, a form of buprenorphine, rather than methadone; her case illustrates the role of medication in pregnancy care without making the two medicines interchangeable.

The account also situates methadone within the history of addiction-maintenance medications. Its discussion points to the Federal Bureau of Narcotics’ framing of methadone and to historical work on the development of buprenorphine as an addiction treatment. The book’s emphasis is on the long-running debate over medication-based treatment, rather than on a detailed history of methadone’s development or a specific dosing protocol at Overmountain Recovery.

Pregnancy and Newborn Care

The book gives methadone a second, clearly defined role in care for newborns with neonatal abstinence syndrome. In Roanoke, about half of the babies born to mothers receiving medication-assisted treatment required neonatal intensive care. Their care usually involved methadone administered twice daily to ease withdrawal, and the average hospital stay was 7.7 days. The figure makes visible a consequence of opioid exposure before birth while also showing that treatment could require sustained hospital support after delivery.

Tess’s pregnancy provides nearby context but a different medication pathway. The Life Center of Galax was among the few Virginia facilities willing to accept patients receiving medication-assisted treatment. Tess took Subutex during the final part of her pregnancy, after spending the earlier months addicted to heroin. Her experience underscores that access depended partly on whether a facility would accept a patient’s existing treatment, while the newborn-care account identifies methadone as a medicine used after birth for some infants’ withdrawal.

Access and Disputed Treatment

Availability remained uneven. The Hope Initiative’s referral system listed thirty-six rehabilitation and aftercare providers, with volunteers matching options to a patient’s finances and the availability of beds. Some volunteers also helped arrange outpatient medication-assisted treatment, but they disagreed about its value; some regarded treating addiction with another drug as wrong despite scientific evidence supporting medication-based care. This division formed part of the environment in which methadone and other treatment medications were offered.

The book also describes financial and institutional barriers around medication treatment. In Tess’s case, insurance covered most of the private treatment center’s bill, while her father paid a $6,500 deductible. Elsewhere, the narrative documents high cash charges and waiting lists for addiction-doctor visits, as well as a federal patient cap that limited the number of people certain certified doctors could treat. Those details concern Tess’s buprenorphine care and the treatment system more broadly; they help explain why the presence of an effective medication did not guarantee timely access.

Significance in the Book

Methadone used at Overmountain Recovery is part of a broader contrast between treatment as a medical practice and the social or institutional resistance that can restrict it. The book records stigma toward medication-assisted treatment in some recovery settings, including people’s belief that taking buprenorphine was not being clean, and describes volunteers who remained divided over medication-based care. It does not establish that every criticism or access barrier applied specifically to methadone. Instead, methadone’s appearances—in treatment, in the history of maintenance medications, and in newborn hospital care—show how one medicine sits within a contested system whose capacity and acceptance often lag behind the need.